TruScreen Group Ltd.NZX: TRU

TRU: FY26 sales projected to surpass NZ$2.8m as public programs and new markets accelerate growth

· Issued by TruScreen Group Ltd.

AI-driven cervical cancer screening device achieved FY25 sales of NZ$1.7m, with China as the dominant market. FY26 sales are forecast to exceed NZ$2.8m, driven by new public screening programs, expanded distribution, and a strategic alliance with Dalton Bio for HPV DNA tests.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

TruScreen Group Ltd. on 6ix

In the deck

Earlier from TruScreen

Later from TruScreen

All TruScreen news releases